249 related articles for article (PubMed ID: 36765318)
21. Long-term retrospective study of retinoic acid combined with arsenic and chemotherapy for acute promyelocytic leukemia.
Zhang X; Wu S; Yang J; Zhang G; Su Y; Zhang M; He J; Shi Y; Li W; Lu P; Lu D
Int J Hematol; 2023 Apr; 117(4):530-537. PubMed ID: 36580227
[TBL] [Abstract][Full Text] [Related]
22. Current standard treatment of adult acute promyelocytic leukaemia.
Lo-Coco F; Cicconi L; Breccia M
Br J Haematol; 2016 Mar; 172(6):841-54. PubMed ID: 26687281
[TBL] [Abstract][Full Text] [Related]
23. Economic evaluation of arsenic trioxide compared to all-trans retinoic acid + conventional chemotherapy for treatment of relapsed acute promyelocytic leukemia in Canada.
Lachaine J; Mathurin K; Barakat S; Couban S
Eur J Haematol; 2015 Sep; 95(3):218-29. PubMed ID: 25354894
[TBL] [Abstract][Full Text] [Related]
24. Treatment of acute promyelocytic leukaemia with all-trans retinoic acid and arsenic trioxide: a paradigm of synergistic molecular targeting therapy.
Zhou GB; Zhang J; Wang ZY; Chen SJ; Chen Z
Philos Trans R Soc Lond B Biol Sci; 2007 Jun; 362(1482):959-71. PubMed ID: 17317642
[TBL] [Abstract][Full Text] [Related]
25. Use of arsenic trioxide in remission induction and consolidation therapy for acute promyelocytic leukaemia in the Australasian Leukaemia and Lymphoma Group (ALLG) APML4 study: a non-randomised phase 2 trial.
Iland HJ; Collins M; Bradstock K; Supple SG; Catalano A; Hertzberg M; Browett P; Grigg A; Firkin F; Campbell LJ; Hugman A; Reynolds J; Di Iulio J; Tiley C; Taylor K; Filshie R; Seldon M; Taper J; Szer J; Moore J; Bashford J; Seymour JF;
Lancet Haematol; 2015 Sep; 2(9):e357-66. PubMed ID: 26685769
[TBL] [Abstract][Full Text] [Related]
26. Comparison of clinical outcomes of patients with relapsed acute promyelocytic leukemia induced with arsenic trioxide and consolidated with either an autologous stem cell transplant or an arsenic trioxide-based regimen.
Thirugnanam R; George B; Chendamarai E; Lakshmi KM; Balasubramanian P; Viswabandya A; Srivastava A; Chandy M; Mathews V
Biol Blood Marrow Transplant; 2009 Nov; 15(11):1479-84. PubMed ID: 19822309
[TBL] [Abstract][Full Text] [Related]
27. Comparison of induction therapy in non-high risk acute promyelocytic leukemia with arsenic trioxide or in combination with ATRA.
Ghavamzadeh A; Jalili M; Rostami S; Yaghmaie M; Aliabadi LS; Mousavi SA; Vaezi M; Fumani HK; Jahani M; Alimoghaddam K
Leuk Res; 2018 Mar; 66():85-88. PubMed ID: 29407588
[TBL] [Abstract][Full Text] [Related]
28. Long-term efficacy and safety of all-trans retinoic acid/arsenic trioxide-based therapy in newly diagnosed acute promyelocytic leukemia.
Hu J; Liu YF; Wu CF; Xu F; Shen ZX; Zhu YM; Li JM; Tang W; Zhao WL; Wu W; Sun HP; Chen QS; Chen B; Zhou GB; Zelent A; Waxman S; Wang ZY; Chen SJ; Chen Z
Proc Natl Acad Sci U S A; 2009 Mar; 106(9):3342-7. PubMed ID: 19225113
[TBL] [Abstract][Full Text] [Related]
29. Long-term follow-up results of cytarabine-containing chemotherapy for acute promyelocytic leukemia.
Park YH; Kim DY; Mun YC; Cho EK; Lee JH; Jo DY; Kim I; Yoon SS; Park SY; Kim B; Bang SM; Kim H; Min YJ; Park JH; Seo JJ; Moon HN; Lee MH; Kim CS; Lee WS; Chong SY; Oh D; Zang DY; Lee KH; Hyun MS; Kim HS; Kim SH; Kwon H; Kim HJ; Park KT; Bae SH; Ryoo HM; Choi JH; Ahn MJ; Yoon HJ; Nam SH; Kim BS; Seong CM
Korean J Intern Med; 2022 Jul; 37(4):841-850. PubMed ID: 35811370
[TBL] [Abstract][Full Text] [Related]
30. Treatment Outcomes Of Patients With Newly Diagnosed Acute Promyelocytic Leukemia; Experience From A Developing Country.
Javed H; Chudary QU; Iftikhar R; Shahbaz N; Ali M; Hamayun S
J Ayub Med Coll Abbottabad; 2022; 34(4):791-796. PubMed ID: 36566401
[TBL] [Abstract][Full Text] [Related]
31. Treating low- and intermediate-risk acute promyelocytic leukemia with and without chemotherapy: A comparison in a tertiary care center.
Saxena M; Madabhavi IV; Patel A; Panchal H; Anand A
J Cancer Res Ther; 2023; 19(5):1371-1378. PubMed ID: 37787311
[TBL] [Abstract][Full Text] [Related]
32. Oral arsenic trioxide, all-trans retinoic acid, and ascorbic acid maintenance after first complete remission in acute promyelocytic leukemia: Long-term results and unique prognostic indicators.
Gill HS; Yim R; Kumana CR; Tse E; Kwong YL
Cancer; 2020 Jul; 126(14):3244-3254. PubMed ID: 32365228
[TBL] [Abstract][Full Text] [Related]
33. Upfront maintenance therapy with arsenic trioxide in acute promyelocytic leukemia provides no benefit for non-t(15;17) subtype.
Chiang YH; Chang YF; Hsieh RK; Lin J; Chen CG; Lim KH; Lin HC; Chang MC
Asia Pac J Clin Oncol; 2012 Dec; 8(4):330-6. PubMed ID: 22897350
[TBL] [Abstract][Full Text] [Related]
34. Long-term outcome of acute promyelocytic leukemia treated with all-
Abaza Y; Kantarjian H; Garcia-Manero G; Estey E; Borthakur G; Jabbour E; Faderl S; O'Brien S; Wierda W; Pierce S; Brandt M; McCue D; Luthra R; Patel K; Kornblau S; Kadia T; Daver N; DiNardo C; Jain N; Verstovsek S; Ferrajoli A; Andreeff M; Konopleva M; Estrov Z; Foudray M; McCue D; Cortes J; Ravandi F
Blood; 2017 Mar; 129(10):1275-1283. PubMed ID: 28003274
[TBL] [Abstract][Full Text] [Related]
35. Incorporation of arsenic trioxide in induction therapy improves survival of patients with newly diagnosed acute promyelocytic leukaemia.
Song X; Hu X; Lü S; Gao L; Chen L; Yang J; Zhang W; Wang J
Eur J Haematol; 2014 Jul; 93(1):54-62. PubMed ID: 24592821
[TBL] [Abstract][Full Text] [Related]
36. Outcomes of high-risk acute promyelocytic leukemia patients treated with arsenic trioxide (ATO)/all trans retinoic acid (ATRA) based induction and consolidation without maintenance phase: A case Series.
Shah G; Mikhail FM; Bachiasvili K; Vachhani P; Erba HP; Papadantonakis N
Hematol Oncol Stem Cell Ther; 2020 Sep; 13(3):143-146. PubMed ID: 31629725
[TBL] [Abstract][Full Text] [Related]
37. Role of arsenic trioxide in acute promyelocytic leukemia.
Iland HJ; Seymour JF
Curr Treat Options Oncol; 2013 Jun; 14(2):170-84. PubMed ID: 23322117
[TBL] [Abstract][Full Text] [Related]
38. Oral arsenic trioxide-based maintenance regimens for first complete remission of acute promyelocytic leukemia: a 10-year follow-up study.
Au WY; Kumana CR; Lee HK; Lin SY; Liu H; Yeung DY; Lau JS; Kwong YL
Blood; 2011 Dec; 118(25):6535-43. PubMed ID: 21998212
[TBL] [Abstract][Full Text] [Related]
39. The efficacy and safety of arsenic trioxide with or without all-trans retinoic acid for the treatment of acute promyelocytic leukemia: a meta-analysis.
Wang H; Chen XY; Wang BS; Rong ZX; Qi H; Chen HZ
Leuk Res; 2011 Sep; 35(9):1170-7. PubMed ID: 21774985
[TBL] [Abstract][Full Text] [Related]
40. [Comparison of efficacy and adverse effects between arsenic trioxide and all-trans retinoic acid in patients with acute promyelocytic leukemia].
Jiao L; Wang SJ; Zhuang JL; Zhao YQ; Zhou DB; Xu Y; Han B; Zhang W; Duan MH; Zou N; Zhu TN; Shen T
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2009 Oct; 31(5):555-8. PubMed ID: 19968069
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]